Brinker Capital Inc. Buys Shares of 99,497 BioDelivery Sciences International, Inc. (NASDAQ:BDSI)

Brinker Capital Inc. bought a new stake in shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 99,497 shares of the specialty pharmaceutical company’s stock, valued at approximately $419,000. Brinker Capital Inc. owned 0.11% of BioDelivery Sciences International as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. NEXT Financial Group Inc lifted its stake in BioDelivery Sciences International by 15.1% during the 3rd quarter. NEXT Financial Group Inc now owns 155,850 shares of the specialty pharmaceutical company’s stock valued at $656,000 after acquiring an additional 20,500 shares during the period. Nisa Investment Advisors LLC bought a new position in shares of BioDelivery Sciences International in the 3rd quarter worth approximately $148,000. River & Mercantile Asset Management LLP bought a new position in shares of BioDelivery Sciences International in the 2nd quarter worth approximately $1,860,000. United Services Automobile Association lifted its stake in shares of BioDelivery Sciences International by 125.1% in the 2nd quarter. United Services Automobile Association now owns 333,209 shares of the specialty pharmaceutical company’s stock worth $1,549,000 after purchasing an additional 185,200 shares during the period. Finally, Nuveen Asset Management LLC bought a new position in shares of BioDelivery Sciences International in the 2nd quarter worth approximately $2,358,000. Institutional investors and hedge funds own 68.51% of the company’s stock.

Several equities analysts have recently weighed in on the stock. William Blair reiterated a “buy” rating on shares of BioDelivery Sciences International in a research note on Tuesday, September 17th. BidaskClub upgraded shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating in a research note on Friday, October 18th. Finally, ValuEngine upgraded shares of BioDelivery Sciences International from a “strong sell” rating to a “sell” rating in a research note on Tuesday. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $6.20.

In related news, Director Mark A. Sirgo sold 24,506 shares of the stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $4.79, for a total value of $117,383.74. Following the completion of the sale, the director now directly owns 1,874,637 shares of the company’s stock, valued at approximately $8,979,511.23. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Francis E. Odonnell, Jr. sold 8,000 shares of the stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $4.29, for a total transaction of $34,320.00. Following the completion of the sale, the director now directly owns 588,754 shares of the company’s stock, valued at $2,525,754.66. The disclosure for this sale can be found here. Insiders sold a total of 340,864 shares of company stock worth $1,648,479 in the last quarter. Company insiders own 8.94% of the company’s stock.

Shares of NASDAQ:BDSI opened at $6.03 on Tuesday. The firm’s 50 day moving average price is $4.82 and its 200-day moving average price is $4.50. BioDelivery Sciences International, Inc. has a twelve month low of $2.80 and a twelve month high of $6.06. The company has a quick ratio of 2.09, a current ratio of 2.34 and a debt-to-equity ratio of 0.88. The stock has a market capitalization of $472.68 million, a PE ratio of -8.26 and a beta of 0.33.

BioDelivery Sciences International (NASDAQ:BDSI) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $0.06 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.06) by $0.12. BioDelivery Sciences International had a negative net margin of 34.73% and a negative return on equity of 0.85%. The firm had revenue of $29.68 million for the quarter, compared to analysts’ expectations of $25.30 million. Analysts expect that BioDelivery Sciences International, Inc. will post -0.04 earnings per share for the current fiscal year.

About BioDelivery Sciences International

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Read More: What is the quiet period?

Institutional Ownership by Quarter for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.